http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정흥호,정호승,김은영,조환익,황주찬,최상원 한국환경과학회 2004 한국환경과학회지 Vol.13 No.6
Polycyclic aromatic hydrocarbons(PAHs) in sediments of Kwangyang bay on Korea, have been investigated by gas chromatography-mass spectrometery (GC/MS). The average content of total PAHs in all samples was 2,211ppb, and the range was from 36 to 22,699pph. The higher concentrations were found in sediment sampled near Kwangyang iron processing plant, Taeindo. The resulting distributions of PAHs according to the number of aromatic ring and molecular ratios of specific aromatic compounds (phenanthrene, anthracene, fluoranthene and pyrene) have been discussed in terms of sample location, origin of the organic matter. Four, five and six rings of PAHs were mainly found near to Kwangyang iron processing plant, and three and four rings near to Yeosu chemical kombinat. This result typically indicated the local characteristics, depending on the origin of PAHs.
Chon Hyung Ku,Song Tae Jun,Yoo Kyoung-Hoon,Hwang Jun Seong,Kim Myung-Hwan,Choi Eun Kwang,Kim Tae Hyeon 거트앤리버 소화기연관학회협의회 2023 Gut and Liver Vol.17 No.6
Background/Aims: Most guidelines recommend surgical resection of all main duct (MD) and mixed-type (MT) intraductal papillary mucinous neoplasms (IPMNs) in suitable patients. However, there is little evidence regarding the malignancy risk of enhancing mural nodules (EMNs) that are present only in the main pancreatic duct (MPD) in patients with MD- and MT-IPMNs. Therefore, this study aimed to identify the clinical and morphological features associated with malignancy in MD- and MT-IPMNs with EMNs only in the MPD. Methods: We retrospectively enrolled 50 patients with MD- and MT-IPMNs with EMNs only in the MPD on contrast-enhanced magnetic resonance imaging. We evaluated the clinical characteristics and preoperative radiologic imaging results of MPD morphology and EMN size and analyzed the risk factors associated with malignancy. Results: Histological findings of EMNs were low-grade dysplasia (38%), malignant lesions (62%), high-grade dysplasia (34%), and invasive carcinoma (28%). On the receiver operating characteristic curve, the cutoff value of EMN size on magnetic resonance imaging for best predicting malignancy was 5 mm (sensitivity, 93.5%; specificity, 52.6%; area under the curve, 0.753). Multivariate analysis showed that only EMN >5 mm (odds ratio, 27.69; confidence interval, 2.75 to 278.73; p=0.050) was an independent risk factor for malignancy. Conclusions: EMNs of >5 mm are associated with malignancy in patients with MD- and MT-IPMNs with EMNs that are present only in the MPD, in accordance with the international consensus guidelines.
Chon, Young Eun,Kim, Dong Joon,Kim, Sang Gyune,Kim, In Hee,Bae, Si Hyun,Hwang, Seong Gyu,Heo, Jeong,Jang, Jeong Won,Lee, Byung Seok,Kim, Hyung Joon,Jun, Dae Won,Kim, Kang Mo,Chung, Woo Jin,Choi, Moon Wolters Kluwer Health 2016 Medicine Vol.95 No.14
<P><B>Abstract</B></P><P>Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type.</P><P>We collected data from 439 patients (HBeAg positive, n = 349; HBeAg negative, n = 90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated.</P><P>In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA < 2000 IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, <I>P</I> = 0.035; at PT6, 35.9% vs 13.3%, <I>P</I> = 0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (<I>P</I> < 0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, <I>P</I> < 0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN α-2a.</P><P>In naïve Korean HBeAg-positive CHB patients treated with PEG-IFN α-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs.</P>
( Young Eun Chon ),( Kyu Sik Jung ),( Seong Gyu Hwang ),( Kyu Sung Rim ),( Mi Na Kim ),( Hana Park ),( Yun Bin Lee ),( Joo Ho Lee ),( Yeonjung Ha ),( Sang Hoon Ahn ),( Do Young Kim ),( Kwang-hyub Han 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Long term suppression of hepatitis B virus with tenofovir (TDF) is known to induce fibrosis regression, and repeated liver stiffness (LS) measurement can indicate the regression of fibrosis. We aimed to investigate predictors for fibrosis improvement assessed by LS changes in patients receiving long-term TDF therapy in chronic hepatitis B (CHB) with liver cirrhosis. Methods: CHB patients with histologically proven liver cirrhosis who received TDF as the first-line therapy from 2011 to 2016 were recruited. LS and controlled attenuation parameter (CAP) measurements were repeated at baseline and 3 years after therapy. Fibrosis improvement was defined as a drop of LS value ≥30% from the baseline. Results: A total of 119 patients were enrolled (mean age 21.3 and male 67.2%). After 3 years of TDF therapy, the mean LS value has significantly improved (from 14.7 kPa to 8.7 kPa, P<0.001), and 85 (71.4%) patients have achieved fibrosis improvement. Predictors associated with improvement of LS were low body mass index (BMI), HBeAg positivity, and low CAP value at baseline. In multivariate analysis, low BMI was a single factor independently associated with fibrosis regression (odds ratio 0.642, 95% CI 0.515-0.800, P<0.001). Patients with BMI<23.5, had a 2.1 times more chance of achieving fibrosis regression compared to those with BMI ≥23.5. (89.2% vs. 42.2%, P=0.001) Conclusions: High BMI was a single significant factor hindering the fibrosis improvement in patients receiving long-term TDF therapy in chronic hepatitis B with liver cirrhosis. Life style modification and BMI reduction should be encouraged to enhance fibrosis improvement.
( Young Eun Chon ),( Hana Park ),( Mi Na Kim ),( Yeonjung Ha ),( Joo Ho Lee ),( Seong Gyu Hwang ),( Kyu Sung Rim ),( Beon Kyung Kim ),( Seung Up Kim ),( Sang Hoon Ahn ),( Do Young Kim ),( Kwang-hyub H 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Neutrophil-lymphocyte ratio (NLR) has recently been reported as a predictor of hepatocellular carcinoma (HCC).<sup>1, 2</sup> We aim to investigate whether NLR is a predictor for patients with HCC undergoing transarterial chemoembolization (TACE) and develop a prediction model based upon it. Methods: 1,697 HCC patients undergoing TACE as a first-line therapy were enrolled from two University Hospitals (derivation set n=1316, external validation set n=381). Serum alpha-feto protein (AFP) level, the Barcelona clinic liver cancer (BCLC) stage, Child-Pugh Class, Tumor Response after TACE, and NLR, which were selected as predictors for overall survival (OS) from a multivariate Cox-regression model were incorporated into a 9-point risk prediction model (ABCRN score). The prognostic performance of ABCRN score was assessed in the derivation set and in the validation set. Results: The time-dependent areas under receiver-operating characteristic curves (AUROCs) for OS of ABCRN score at 1-, 3- and 5-years were 0.808, 0.724 and 0.688 in the derivation set, and those were 0.848, 0.662, and 0.717, in the validation set. ABCRN score had the highest AUROCs for OS at 1/3/5 years, compared with ART (0.577/0.505/0.655), ABCR (0.776/0.645/0.600), and SNACOR (0.770/0.662/0.634) scores, respectively, with statistical significances (all P values <0.05 vs. ABCRN score). Patients were stratified into the three risk groups according to ABCRN score (low,0-2; intermediate,3-6; high,7- 9). Patients with high risk group had a significantly higher mortality risk compared to the intermediate (hazard ratio[HR], 2.8; P<0.001) or low-risk group (HR,. 10.7; P<0.001) Conclusions: : Prognostic performance of ABCRN score in patients with HCC treated with TACE was remarkable and it was better compared to conventional scores. This score will help for further guiding future HCC treatment direction.
( Young Eun Chon ),( Dong Joon Kim ),( Sang Gyune Kim ),( In Hee Kim ),( Si Hyun Bae ),( Seong Gyu Hwang ),( Jeong Heo ),( Jeong Won Jang ),( Byung Seok Lee ),( Hyung Joon Kim ),( Dae Won Jun ),( Gang 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Until today, there is currently no data available on the efficacy, safety, and tolerability of pegylated interferon alfa 2a (PEG-IFNa-2a) in Korean patients with chronic hepatitis B (CHB), who are known to have mostly HBV genotype C. Methods: We collected data from 18 institutes of 451 Korean patients with CHB who were treated with PEG-IFNa-2a as a first line therapy (370 patients with HBeAg positive and 81 with HBeAg negative). Treatment responses at the end of treatment (ET) and at 6 months post-treatment (PT6) were compared between patients treated for 24 weeks vs. 48 weeks, and adverse events were evaluated. Results: In HBeAg-positive patients, the patients who had received PEG-IFNa-2a for 48 weeks than 24 weeks achieved significantly higher virological response (HBV DNA < 2,000 IU/mL) (48 vs. 24 weeks at ET, 44.4% vs. 27.2%, p = 0.005; at PT6, 46.7% vs. 17.2%, p=0.001). Complete virological response (HBV DNA < 60 IU/mL) at ET was also achieved in more patients with a longer treatment (48 vs. 24 weeks 22.0% vs. 13.0%, p=0.005). HBeAg seroconversion rate at ET was 18.1% with 48 weeks treatment, which is significantly higher than 10.1% (p=0.012) with 24 weeks treatment. This finding was continued to PT6 (23.7% vs. 17.2%, p = 0.028). The rate of ALT normalization was increased from 61.4% at ET to 76.8% at PT6 on 48 weeks-treatment. HBsAg seroconversion was not common (48 vs. 24 weeks at ET, 0.4% vs. 0%; at PT6, 0.8% vs. 0%). In HBeAg-negative patients, virologic response at ET was higher than that in HBeAg-positive patients following 48 weeks treatment (serum HBV DNA< 60 and < 2,000 IU/mL; 60.8% and 87.8%, respectively). HBsAg seroconversion was 1.4% at ET and it was maintained at PT6. Adverse events were typical of those associated with PEG-IFNa-2a. Conclusion: In Korean CHB patients, PEG-IFNa-2a showed substantial treatment response and good tolerability. In patients with HBeAg-positive CHB, the longer treatment of PEG-IFNa-2a (48 weeks rather than 24 weeks) was more efficacious with similar safety profiles.